Company intelligence / Profile preview
Shanton Pharma
Singaporeshantonpharma.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
In March 2025, Shanton Pharma reported positive topline data from their Phase IIb study, indicating that SAP-001 met its primary endpoint by significantly reducing serum urate levels in refractory gout patients[5]. The RID GOUT Study was a six-month, multi-center, randomized, double-blind, placebo-controlled study that enrolled 87 patients across 21 U.S. sites[5].
- Therapeutic areas
- DermatologyMetabolic DisordersRheumatology
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Beyond the preview
Go deeper on Shanton Pharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Shanton Pharma.